552 related articles for article (PubMed ID: 19076171)
41. Characterization of an amyloid fibril protein from localized amyloidosis of the skin as lambda immunoglobulin light chains of variable subgroup I (A lambda I).
Husby G; Sletten K; Blumenkrantz N; Danielsen L
Clin Exp Immunol; 1981 Jul; 45(1):90-6. PubMed ID: 6796317
[TBL] [Abstract][Full Text] [Related]
42. Diffuse parenchymal amyloidosis of lungs and breast. Its association with diffuse plasmacytosis and kappa-chain gammopathy.
Hardy TJ; Myerowitz RL; Bender BL
Arch Pathol Lab Med; 1979 Oct; 103(11):583-5. PubMed ID: 114145
[TBL] [Abstract][Full Text] [Related]
43. Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis.
Helms LR; Wetzel R
J Mol Biol; 1996 Mar; 257(1):77-86. PubMed ID: 8632461
[TBL] [Abstract][Full Text] [Related]
44. [Comparative analysis of immunoglobulin free light chains quantification by Freelite™ (The Binding Site) and N Latex FLC (Siemens) methods].
Schneider N; Wynckel A; Kolb B; Sablon E; Gillery P; Maquart FX
Ann Biol Clin (Paris); 2013; 71(1):13-9. PubMed ID: 23396425
[TBL] [Abstract][Full Text] [Related]
45. [Clinical significance of measurement of free light chains].
Matsuda M
Rinsho Byori; 2010 Apr; 58(4):401-4. PubMed ID: 20496770
[TBL] [Abstract][Full Text] [Related]
46. Serum free light chains for monitoring multiple myeloma.
Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
[TBL] [Abstract][Full Text] [Related]
47. [Light chain or monoclonal immunoglobulin deposition disease: physiopathogenic concepts].
Preud'homme JL; Mihaesco E; Guglielmi P; Morel-Maroger L; Ganeval D; Danon F; Brouet JC; Mihaesco C; Seligmann M
Nouv Presse Med; 1982 Nov; 11(44):3259-63. PubMed ID: 6818521
[TBL] [Abstract][Full Text] [Related]
48. AL-amyloidosis is underdiagnosed in renal biopsies.
Novak L; Cook WJ; Herrera GA; Sanders PW
Nephrol Dial Transplant; 2004 Dec; 19(12):3050-3. PubMed ID: 15507480
[TBL] [Abstract][Full Text] [Related]
49. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect.
Shaheen SP; Levinson SS
Clin Chim Acta; 2009 Aug; 406(1-2):162-6. PubMed ID: 19410572
[TBL] [Abstract][Full Text] [Related]
50. Nonamyloidotic monoclonal immunoglobulin deposits lack amyloid P component.
Gallo G; Picken M; Frangione B; Buxbaum J
Mod Pathol; 1988 Nov; 1(6):453-6. PubMed ID: 3146753
[TBL] [Abstract][Full Text] [Related]
51. [Amyloid neuropathy associated with a benign monoclonal gammopathy (lambda light chains)].
Graveleau P; Dairou R; Tritschler JC; Hénin D; Masson M; Cambier J
Rev Neurol (Paris); 1978 Dec; 134(12):773-80. PubMed ID: 224439
[TBL] [Abstract][Full Text] [Related]
52. Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy.
Fulton RB; Fernando SL
Ann Clin Biochem; 2009 Sep; 46(Pt 5):407-12. PubMed ID: 19641008
[TBL] [Abstract][Full Text] [Related]
53. The ultrastructural basis of renal pathology in monoclonal gammopathies.
Santostefano M; Zanchelli F; Zaccaria A; Poletti G; Fusaroli M
J Nephrol; 2005; 18(6):659-75. PubMed ID: 16358223
[TBL] [Abstract][Full Text] [Related]
54. Detailed structural analysis of amyloidogenic wild-type transthyretin using a novel purification strategy and mass spectrometry.
Kingsbury JS; Théberge R; Karbassi JA; Lim A; Costello CE; Connors LH
Anal Chem; 2007 Mar; 79(5):1990-8. PubMed ID: 17261023
[TBL] [Abstract][Full Text] [Related]
55. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.
Andrich K; Hegenbart U; Kimmich C; Kedia N; Bergen HR; Schönland S; Wanker E; Bieschke J
J Biol Chem; 2017 Feb; 292(6):2328-2344. PubMed ID: 28031465
[TBL] [Abstract][Full Text] [Related]
56. Lambda light chain deposition disease presenting as an amyloid-like arthropathy.
Rivest C; Turgeon PP; Senécal JL
J Rheumatol; 1993 May; 20(5):880-4. PubMed ID: 8336318
[TBL] [Abstract][Full Text] [Related]
57. IgD amyloid in IgD-lambda monoclonal conjunctival amyloidosis. A case report.
Schaldenbrand JD; Keren DF
Arch Pathol Lab Med; 1983 Dec; 107(12):626-8. PubMed ID: 6416220
[TBL] [Abstract][Full Text] [Related]
58. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
[TBL] [Abstract][Full Text] [Related]
59. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.
Gertz MA; Leung N; Lacy MQ; Dispenzieri A; Zeldenrust SR; Hayman SR; Buadi FK; Dingli D; Greipp PR; Kumar SK; Lust JA; Rajkumar SV; Russell SJ; Witzig TE
Nephrol Dial Transplant; 2009 Oct; 24(10):3132-7. PubMed ID: 19403931
[TBL] [Abstract][Full Text] [Related]
60. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.
Gertz MA; Comenzo R; Falk RH; Fermand JP; Hazenberg BP; Hawkins PN; Merlini G; Moreau P; Ronco P; Sanchorawala V; Sezer O; Solomon A; Grateau G
Am J Hematol; 2005 Aug; 79(4):319-28. PubMed ID: 16044444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
